| name | icsm-select-fertility-preserving-strategy |
| description | Guides selection among hCG, recombinant FSH, aromatase inhibitors, SERMs, combined testosterone/hCG, or intranasal testosterone for men on or after testosterone therapy who wish to preserve fertility. Triggers when a clinician manages a man requesting sperm maintenance or spermatogenesis recovery while on or after testosterone and asks how to maintain sperm production or which agent to use. |
Choose a fertility-preserving strategy for men on or after testosterone therapy
STEP 1 — Gather Information
Collect indication (post‑testosterone therapy or post‑AAS abuse), presence of functional gonadal cells, contraindications (e.g., untreated prostate cancer, severe cardiovascular disease, elevated hematocrit, gynecomastia, severely low testosterone), desired duration of therapy, and expected outcomes (testosterone rise, spermatogenesis return, testis volume).
STEP 2 — Rule In / Rule Out
Determine if the patient has functional Leydig (gonadal) cells capable of responding to LH/hCG; if yes, proceed to consider hCG‑based strategies; if no, rule out hCG and move to gonadotropin‑ or SERM‑based options.
STEP 3 — Classify or Stratify
For those with functional gonadal cells, stratify by prior response to hCG (naïve vs failed) and by contraindications (e.g., gynecomastia favors aromatase inhibitor; inability to produce endogenous gonadotropins favors SERM or rFSH); for those without functional gonadal cells, consider rFSH ± hCG or SERM based on pituitary capacity.
STEP 4 — Decide
Choose the agent matching the stratum: hCG monotherapy for naïve functional gonadal cells; add recombinant FSH if hCG fails; use aromatase inhibitor (e.g., anastrozole) for low T/E2 ratio or gynecomastia prevention; use SERM (clomiphene/enclomiphene) for pituitary‑gonadal axis recovery when endogenous gonadotropins can be stimulated; consider intranasal testosterone if the patient requires ongoing testosterone therapy while actively trying to conceive.
Clinical Guardrails / Mimics / Pitfalls
Do not use testosterone monotherapy in men seeking fertility; avoid hCG in patients with primary testicular failure or absent Leydig cell function; avoid aromatase inhibitors in men with severely low testosterone levels; avoid SERMs in patients with gonadotropin failure; monitor hematocrit and prostate cancer status before intranasal testosterone; counsel that off‑label use requires shared decision‑making.
Concrete Clinical Example
A 38‑year‑old man on testosterone cypionate 100 mg weekly for 4 months presents with desire to father a child. Semen analysis shows azoospermia. Examination reveals normal testicular volume, LH 1.2 IU/L, FSH 1.5 IU/L, testosterone 350 ng/dL. No contraindications. He is started on hCG 1500 IU subcutaneously three times weekly; after 3 months, semen analysis returns 15 million/mL total motile count.
Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), International Consultation on Sexual Medicine, 2025, DOI: 10.1093/sxmrev/qeaf036
